Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results

V. Sahai; W. Saif; A. Kalyan; P. Philip; C. Rocha-Lima; A. Ocean; M. Ondovik; D. Simeone; M. Karnoub; C. Louis; V. Picozzi

doi:10.1093/annonc/mdy151.154

Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results

V. Sahai, W. Saif, A. Kalyan, P. Philip, C. Rocha-Lima, A. Ocean, M. Ondovik, D. Simeone, M. Karnoub, C. Louis, V. Picozzi

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	v43
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy151.154
State	Published - Jun 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy151.154

Cite this

Sahai, V., Saif, W., Kalyan, A., Philip, P., Rocha-Lima, C., Ocean, A., Ondovik, M., Simeone, D., Karnoub, M., Louis, C., & Picozzi, V. (2018). Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v43. https://doi.org/10.1093/annonc/mdy151.154

Sahai, V. ; Saif, W. ; Kalyan, A. ; Philip, P. ; Rocha-Lima, C. ; Ocean, A. ; Ondovik, M. ; Simeone, D. ; Karnoub, M. ; Louis, C. ; Picozzi, V. / Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer : Phase I results. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. v43.

@article{473ce341324b41718dbc600b35e54d84,

title = "Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results",

author = "V. Sahai and W. Saif and A. Kalyan and P. Philip and C. Rocha-Lima and A. Ocean and M. Ondovik and D. Simeone and M. Karnoub and C. Louis and V. Picozzi",

year = "2018",

month = jun,

day = "1",

doi = "10.1093/annonc/mdy151.154",

language = "English (US)",

volume = "29",

pages = "v43",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Sahai, V, Saif, W, Kalyan, A, Philip, P, Rocha-Lima, C, Ocean, A, Ondovik, M, Simeone, D, Karnoub, M, Louis, C & Picozzi, V 2018, 'Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. v43. https://doi.org/10.1093/annonc/mdy151.154

Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer : Phase I results. / Sahai, V.; Saif, W.; Kalyan, A.; Philip, P.; Rocha-Lima, C.; Ocean, A.; Ondovik, M.; Simeone, D.; Karnoub, M.; Louis, C.; Picozzi, V.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.06.2018, p. v43.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer

T2 - Phase I results

AU - Sahai, V.

AU - Saif, W.

AU - Kalyan, A.

AU - Philip, P.

AU - Rocha-Lima, C.

AU - Ocean, A.

AU - Ondovik, M.

AU - Simeone, D.

AU - Karnoub, M.

AU - Louis, C.

AU - Picozzi, V.

PY - 2018/6/1

Y1 - 2018/6/1

UR - http://www.scopus.com/inward/record.url?scp=85068486302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068486302&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy151.154

DO - 10.1093/annonc/mdy151.154

M3 - Article

C2 - 32177135

VL - 29

SP - v43

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -

Sahai V, Saif W, Kalyan A, Philip P, Rocha-Lima C, Ocean A et al. Open-label, multicenter, single-arm study of FABLOx (metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin) in patients with metastatic pancreatic cancer: Phase I results. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Jun 1;29:v43. https://doi.org/10.1093/annonc/mdy151.154